C07K 16/102
Coronaviridae
Official title: Coronaviridae (F)
C07K16/102 (Coronaviridae) appears on 213 US grants and 797 published applications in this corpus.
Search patents in C07K- Granted patents
- 213
- Published applications
- 797
- Assignees
- 488
- Inventors
- 2,442
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 7 |
| 2006 | 1 | 10 |
| 2007 | 0 | 6 |
| 2008 | 3 | 4 |
| 2009 | 2 | 4 |
| 2010 | 4 | 3 |
| 2011 | 1 | 5 |
| 2012 | 1 | 2 |
| 2013 | 2 | 2 |
| 2014 | 2 | 2 |
| 2015 | 1 | 5 |
| 2016 | 1 | 9 |
| 2017 | 4 | 9 |
| 2018 | 7 | 12 |
| 2019 | 8 | 9 |
| 2020 | 14 | 12 |
| 2021 | 20 | 59 |
| 2022 | 26 | 76 |
| 2023 | 22 | 188 |
| 2024 | 34 | 187 |
| 2025 | 30 | 124 |
| 2026 | 27 | 61 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Use of SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies to treat COVID-196 Oct 2026US 12,753,417 B2The Feinstein Institutes for Medical Research
- Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)6 Oct 2026US 12,754,184 B2Navigo Proteins GmbH
- Follicular helper T (TFH) cells specific to SARS-COV-2 virus15 Sep 2026US 12,734,232 B2The University of Osaka
- Methods of identifying subjects having an increased risk of developing a coronavirus infection and treatment thereof15 Sep 2026US 12,735,752 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for the detection and treatment of SARS-CoV-2 virus infection1 Sep 2026US 12,724,030 B2Georgia Tech Research Corporation
- Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf)1 Oct 2026US 2026/0295009 A1Partner Therapeutics, Inc.
- Compositions and methods for the treatment of immunodeficiency24 Sep 2026US 2026/0285950 A1Adma Biomanufacturing, LLC
- Intranasal Administration of a Polyclonal Blood Derivative Directed Against a Pathogen Agent for the Prevention and/or Treatment of an Airborne Disease24 Sep 2026US 2026/0285951 A1Prevor International
- Antibodies that bind to multiple sarbecoviruses17 Sep 2026US 2026/0274928 A1Vir Biotechnology, Inc.
- Sars-cov2 antibodies and methods of use thereof10 Sep 2026US 2026/0265350 A1Invivyd, Inc.
Most cited
By later US patents
- Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)129US 7,339,051 B2Isis Pharmaceuticals, Inc. · 2008
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Binding molecules against SARS-coronavirus and uses thereof58US 7,696,330 B2Crucell Holland B. V. · 2010
- Betacoronavirus mRNA vaccine46US 10,702,600 B1ModernaTX, Inc. · 2020
- Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments41US 10,787,501 B1Regeneron Pharmaceuticals, Inc. · 2020